Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 1,280 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Infection Prophylaxis Clear all

Conditions: HIV Infections
Interventions: Chlorhexidine gluconate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2007
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: COVID-19
Interventions: Motivational Interviewing, COVID-19 Symptom Monitoring System, Motivational Interviewing and COVID-19 Symptom Monitoring System, Supportive Services; Behavioral · Other
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Whiteriver, Arizona

Conditions: HIV, Acquired Immunodeficiency Syndrome, Alcoholism, Alcoholic Intoxication, Substance-Related Disorders
Interventions: Motivational Interviewing, Email Feedback, Usual Care; Behavioral · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 100 Years
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Invasive Fungal Infections, Hematologic Malignancies
Interventions: Posaconazole, ABLC; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Influenza, Virus Diseases
Interventions: H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hepatitis C, HepatoCellular Carcinoma
Interventions: Mailed outreach; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 53 Years to 74 Years
Enrollment: 12,386 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Acquired Immunodeficiency Syndrome, Candidiasis, Oral Candidiasis
Interventions: fluconazole; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hiv, Sexually Transmitted Diseases, Aging
Interventions: safe sex and HIV/STD prevention education via a website, written materials on safe sex; Behavioral · Other
Lead sponsor: Environment and Health Group, Inc.; Industry
Eligibility: 50 Years to 70 Years · Female only
Enrollment: 331 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: anti-thymocyte globulin, rituximab, sirolimus, tacrolimus, laboratory biomarker analysis, allogeneic hematopoietic stem cell transplantation, management of therapy complications, peripheral blood stem cell transplantation; Biological · Drug · Other + 1 more
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: COVID-19, SARS-CoV-2 Infection
Interventions: CoTend-BXBB (SARS2-30404), CoTend-s3BXBB (SARS2-17032), Placebo; Biological
Lead sponsor: Kara Chew; Other
Eligibility: 40 Years to 64 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Los Angeles, California • San Francisco, California

Conditions: Urinary Tract Infection(UTI)
Interventions: Insertion of a urinary catheter coated with benign E. coli; Device
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prophylaxis for Herpes Simplex
Interventions: Herpes simplex candidate vaccine- adjuvanted GSK 208141, Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 7,460 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1996 – 1999
U.S. locations: 36
States / cities: La Jolla, California • Middle Valley, California • San Diego, California + 31 more

Conditions: Wounds and Injuries, Respiratory Failure, Pneumonia, Ventilator-Associated
Interventions: Chlorhexidine gluconate; Drug
Lead sponsor: Nicholas M Mohr; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: HIV, Sexually Transmitted Diseases, Pregnancy, HIV Infections
Interventions: HIV, STD, Pregnancy Prevention Curriculum; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Late Effects of Surgery, Staphylococcus Aureus, Surgical Site Infection
Interventions: daptomycin; Drug
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 19 Years to 74 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Torrance, California

Conditions: Pregnancy in Adolescence, Sexually Transmitted Diseases
Interventions: Wrap It Up (WIU); Behavioral
Lead sponsor: ETR Associates; Other
Eligibility: 16 Years to 19 Years
Enrollment: 1,120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Scotts Valley, California

Conditions: Epstein-Barr Virus Infections, Lymphoproliferative Disorders
Interventions: Intravenous injection of EBV specific CTLs; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 2
States / cities: Houston, Texas

Conditions: HIV Infections
Interventions: Project POWER HIV Risk-reduction Intervention, NC DOC Standard of Care for STIs; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older · Female only
Enrollment: 598 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Raleigh, North Carolina • Rocky Mount, North Carolina

Conditions: Surgical Site Infection
Interventions: Ertapenem, Cefazolin and Metronidazole.; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections, Epstein-Barr Virus Infections, Human Herpes Virus-6 Infection, JC Virus Infection
Interventions: Posoleucel (ALVR105), Placebo; Biological
Lead sponsor: AlloVir; Industry
Eligibility: Not listed
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 35
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 31 more

Conditions: Urinary Tract Infection
Interventions: Once Daily Cranberry Capsule, Twice Daily Cranberry Capsules; Dietary Supplement
Lead sponsor: Yale University; Other
Eligibility: 60 Years and older
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: HIV -1 Infection
Interventions: Live Biotherapeutic Product L. jensenii 1153-1666, Placebo; Drug
Lead sponsor: Craig Cohen, MD, MPH; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Infections
Interventions: Cefazolin 3gm for Injection USP and Dextrose Injection USP; Drug
Lead sponsor: B. Braun Medical Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Columbus, Georgia • Oklahoma City, Oklahoma

Conditions: HIV Infections
Interventions: Community Mobilization; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 14
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 11 more

Search by objective public record fields.

A Study of Chlorhexidine in the Prevention of HIV-1 Transmission From Mothers to Their Babies

Protecting Native Families From COVID-19

Primary Care-Based Interventions to Reduce Alcohol Use Among HIV Patients

Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)

Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study A)

STOP HCC: Mailed HCV Treatment Outreach Program for HCC Prevention

Fluconazole Prophylaxis of Thrush in AIDS

Prevention of HIV/AIDS and STDs in Women Over Fifty

Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation

A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses

E. Coli for Prevention of Catheter UTI in SCI Patients

Safety Evaluation of Herpes Simplex Candidate Vaccine (gD2t) With Adjuvant in HSV Seropositive / Seronegative Subjects

Prehospital Ventilator-Associated Pneumonia Prevention Trial

Safer Choices 2 - HIV, STD, & Pregnancy Prevention Program

Pharmacokinetics of Daptomycin During Cardiopulmonary Bypass Surgery

Wrap It Up Rigorous Evaluation

Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs).

Project POWER, Adapting Project SAFE: Reducing STD/HIV Risk in Women Prisoners

PRevention Of Trauma-related Infections Through an Embedded Clinical Trials Network

Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

Cranberry for UTI Prevention in Residents of Long Term Care Facilities

Safety Study of MucoCept-CVN

Pharmacokinetics and Safety of Cefazolin 3gm DUPLEX in Adults

C2P Mobilization Intervention (Pilot)